Vineet Laboratories Limited (VINEETLAB) fundamentals
Vineet Laboratories Limited is a listed company in Pharmaceuticals & Biotechnology, part of the Healthcare sector, listed on the NSE as VINEETLAB (ISIN INE505Y01010). This page carries its reported financials, balance sheet, cash flow, shareholding pattern and valuation ratios.
What Vineet Laboratories Limited does
Vineet Laboratories Limited is an India-based company engaged in the business of drug intermediates and bulk drugs. The Company specializes in pharmaceutical intermediates and fine chemicals. Its active pharmaceutical ingredient (API) intermediates products include Lopinavir, Ritonavir, Efavirenz, Nadolol, Glimepiride, Celecoxib, and Piroctone Olanine. Its fine chemicals and reagents include Isopropyl-beta-D-thiogalactopyranoside, 4-Nitrophenyl phosphate disodium salt, 5-Bromo-4-chloro-3-indolyl-beta-D-galactopyranoside (X-Gal), 5-Acetyl thiophene-2-carboxilic acid, n-Butyl Lithium, n-Butyl magnesium chloride, 3-Furaldehyde, 3-bromofuran, 1-methyl-imidazole-2-carboxaldehyde, 6-Aminouracil, Ethyldiazo acetate, and Phenylboronic acid. The Company also exports API intermediates, fine chemicals, and custom synthesis molecules.
Valuation and market data
| Last close | ₹36.00 |
|---|---|
| Market capitalisation | ₹33 crore |
| Enterprise value | ₹38 crore |
| P/E (TTM) | 0.00 |
| Price to book | 2.27 |
| Price to sales (TTM) | 0.56 |
| Book value per share | ₹15.89 |
| Dividend yield | 0.00% |
| Sector | Healthcare |
| Industry | Pharmaceuticals & Biotechnology |
| Listed since | Tue Jun 15 |
Annual results
| Period | Revenue | Profit before tax | Net profit | EPS |
|---|---|---|---|---|
| Mar 2026 | ₹60 crore | ₹1 crore | ₹1 crore | 0.00 |
| Mar 2025 | ₹77 crore | ₹-21 crore | ₹-20 crore | -21.90 |
| Mar 2024 | ₹151 crore | ₹0 crore | ₹1 crore | 1.11 |
| Mar 2023 | ₹212 crore | ₹2 crore | ₹1 crore | 1.36 |
| Mar 2022 | ₹191 crore | ₹9 crore | ₹7 crore | 7.16 |
Figures are as reported (standalone), in ₹ crore.
Shareholding pattern
As of Jun 2026:
| Promoters | 6.0% |
|---|---|
| Foreign institutions (FII) | 0.5% |
| Mutual funds | 0.0% |
| Other domestic institutions | 0.0% |
| Retail and others | 93.5% |
More on BreakPoint
FundaX company research covers every listed company with reported financials. BreakPoint Pro adds the BreakPoint iQ score, the screener and the multibagger board.
Data is sourced from exchange filings and vendor feeds and is for research, not investment advice. Figures can be restated by the company after publication.